EFFECT filed Aug 28, 2026 at 00:15 ET
Oruka Therapeutics' S-3 shelf registration (File No. 333-298488) became effective on August 27, 2026. This allows the company to sell securities at any time, creating potential dilution overhang. The effectiveness follows a prior S-3 filed in April 2026, and the cross-filing actuarial verdict confirms this is an amplifier, the shelf context amplifies the impact of the IPO context, meaning the market should price in the increased flexibility for capital raising.